Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma

Inclusion Criteria: * Male and/or female subjects ≥12 to \< 18 years of age (for Cohorts 1, 2, and 3 as indicated in the study design). * Male and/or non-reproductive female subjects between 18 and 50 years of age, inclusive (for cohort 4). * Females of non-reproductive potential must have documented medical history (ie, postmenopausal by history - no menses for 1 year - and follicle-stimulating hormone value (FSH) consistent with postmenopausal status per laboratory ranges; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). * Females of child-bearing potential and females who cannot document non-reproductive potential must agree to use highly effective methods of birth control for the duration of the study and for 2 weeks after study drug administration. Males whose partners are of child bearing potential must agree to use highly effective methods of birth control for the duration of the study and continuing for 12 weeks after study drug administration. Highly effective methods of birth control (i.e., those with a failure rate of less than 1% per year) include sexual abstinence (males, females), vasectomy or a condom supplemented with the use of a spermicide (males) and occlusive cap (diaphragm or cervical/vault caps), hormonal birth control, or intrauterine device (IUD) used by the female partner. * Male subjects whose partners become pregnant during the study must practice sexual abstinence or use a condom with sperm…